SMYD2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.34149999389643E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.57336999999647E-05 |
Normal-vs-Stage2 |
1.724390E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
2.318300E-02 |
Stage1-vs-Stage2 |
1.830850E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
2.761000E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
9.960000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.01380000453E-08 |
Normal-vs-AfricanAmerican |
4.718600E-01 |
Normal-vs-Asian |
1.563360E-01 |
Caucasian-vs-AfricanAmerican |
5.888200E-01 |
Caucasian-vs-Asian |
3.701200E-01 |
AfricanAmerican-vs-Asian |
8.698600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.229150E-04 |
Normal-vs-Female |
1.98399999999932E-05 |
Male-vs-Female |
6.719400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
5.402000E-03 |
Normal-vs-Extreme_Weight |
2.16559999999255E-05 |
Normal-vs-Obese |
2.324200E-02 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
6.145600E-01 |
Normal_Weight-vs-Obese |
9.711200E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
6.216600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.975020E-01 |
Normal-vs-Age(41-60Yrs) |
7.82980000000322E-05 |
Normal-vs-Age(61-80Yrs) |
5.89570000000261E-05 |
Normal-vs-Age(81-100Yrs) |
4.75479999817452E-08 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.095300E-03 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.658400E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.694440E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.137200E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.126800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.506600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
3.435200E-01 |
Normal-vs-Grade 3 |
3.028800E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
7.213000E-01 |
Grade 2-vs-Grade 4 |
3.435200E-01 |
Grade 3-vs-Grade 4 |
3.028800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
3.20029999945071E-07 |
Normal-vs-N1 |
5.506000E-02 |
N0-vs-N1 |
1.716020E-01 |
|
|